OncoMatch/Clinical Trials/NCT06185205
ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy
Is NCT06185205 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Accelerated partial breast irradiation for breast cancer.
Treatment: Accelerated partial breast irradiation — The purpose of this study is to compare any good and bad effects of giving radiation treatment for breast cancer in 3 treatments over about 2 days.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Allowed: HER2 (ERBB2) overexpression or amplification
If the tumor is human epidermal growth factor receptor 2 (HER2)-positive, the patient must receive HER2-directed therapy.
Allowed: ESR1 positive
estrogen receptor, Her2 = human epidermal growth factor receptor 2, PR = progesterone receptor negative (ER+PR+HER2-)
Allowed: PR (PGR) positive
estrogen receptor, Her2 = human epidermal growth factor receptor 2, PR = progesterone receptor negative (ER+PR+HER2-)
Allowed: HER2 (ERBB2) negative
estrogen receptor, Her2 = human epidermal growth factor receptor 2, PR = progesterone receptor negative (ER+PR+HER2-)
Disease stage
Required: Stage TIS (TNM)
Grade: G1G2 (Not specified)
T stage of Tis, T1, or T2. T2 tumors must be ≤3 cm in maximum diameter
Prior therapy
Must have received: lumpectomy
Previous lumpectomy with surgical margins histologically free of invasive tumor and DCIS as determined by the pathologist.
Cannot have received: breast or thoracic radiation therapy
Prior breast or thoracic radiation therapy (RT) for any condition
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Virginia Commonwealth University · Richmond, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify